Clinical study
Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease

https://doi.org/10.1016/0002-9343(90)90522-FGet rights and content

Abstract

purpose: Methotrexate (MTX), when used to treat malignancy or psoriasis, has been implicated in anecdotal reports as a teratogen or abortifacient in the first trimester of pregnancy. We are unaware of any previous reports that describe the course of gestation and the effect on subsequent offspring in patients treated with low-dose oral MTX for rheumatoid arthritis, and therefore present our experience.

patients and methods: We report on eight women experiencing 10 pregnancies. Mean number of weeks of gestation while taking MTX was 7.5 (range 2 to 20 weeks). Outcome of pregnancies included five full-term babies (FTB), three spontaneous abortions (SAB), and two elective abortions.

results: There were no significant differences in either the FTB or SAB group when considering risk factors including smoking, alcohol, concomitant medications, and age. One of three in the SAB group had recurrent abortions prior to MTX therapy. All five of the FTB group had uncomplicated pregnancies and deliveries. All offspring were of normal height and weight at birth with no physical abnormalities. All children reached growth, development, and intellectual stages normally, and their present mean age is 11.5 years. No observed learning disabilities or medical abnormalities have occurred in any of these children.

conclusion: In this uncontrolled study we failed to demonstrate tertogenicity of MTX. However, the possibility of abortion due to MTX use remains.

References (21)

There are more references available in the full text version of this article.

Cited by (216)

  • Chemotherapy in pregnancy

    2021, Clinical Pharmacology During Pregnancy
  • Fetal methotrexate syndrome: A systematic review of case reports

    2019, Reproductive Toxicology
    Citation Excerpt :

    However, this was not possible as in most cases it could not be traced to which population the patient belonged. It is important to keep in mind that methotrexate does not always cause embryopathy [5,35,36] and that the exact risk of congenital malformations after in utero exposure to methotrexate is unclear. The variability in threshold of methotrexate teratogenicity might be explained by the combination of methotrexate dose, route of administration, timing and individual differences in sensitivity to methotrexate.

  • Special Issues in Pregnancy

    2019, Abeloff’s Clinical Oncology
View all citing articles on Scopus

This study was presented in part at the 51st Annual Meeting of the American Rheumatism Association, Washington, D.C., June 1987

View full text